|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Bizuayehu HM, Ahmed KY, Kibret GD, Dadi
AF, Belachew SA, Bagade T, Tegegne TK, Venchiarutti RL, Kibret KT,
Hailegebireal AH, et al: Global disparities of cancer and its
projected burden in 2050. JAMA Netw Open. 7:e24431982024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tanaka M, Lum L, Hu KH, Chaudhary P,
Hughes S, Ledezma-Soto C, Samad B, Superville D, Ng K, Chumber A,
et al: Tumor cell heterogeneity drives spatial organization of the
intratumoral immune response. J Exp Med. 222:e202422822025.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
MacDonald WJ, Purcell C, Pinho-Schwermann
M, Stubbs NM, Srinivasan PR and El-Deiry WS: Heterogeneity in
cancer. Cancers. 17:4412025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang J, Chen Q, Shan Q, Liang T, Forde P
and Zheng L: Clinical development of immuno-oncology therapeutics.
Cancer Lett. 617:2176162025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh
M, Nabavi N, Sethi G, Zhao P and Liu S: Advances in cancer
immunotherapy: Historical perspectives, current developments, and
future directions. Mol Cancer. 24:1362025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saw PE, Liu Q, Wong PP and Song E: Cancer
stem cell mimicry for immune evasion and therapeutic resistance.
Cell Stem Cell. 31:1101–1112. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barkley D, Moncada R, Pour M, Liberman DA,
Dryg I, Werba G, Wang W, Baron M, Rao A, Xia B, et al: Cancer cell
states recur across tumor types and form specific interactions with
the tumor microenvironment. Nat Genet. 54:1192–1201. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang X, Wang J, Wang Q, Ding G, Huang Y
and Feng Y: Precision cytokine modulation to overcome tumor
microenvironment-driven resistance to immune checkpoint blockade.
Biochim Biophys Acta Rev Cancer. 1881:1895362026. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wickramasekara R, Jones V, Zhao Y, Luo S,
Sun G and Huang RP: Mechanisms of therapy resistance in the tumor
microenvironment: Insights from antibody array-based cytokine
profiling. Drug Resist Updat. 86:1013782026. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cen X, Lan Y, Zou J, Chen R, Hu C, Tong Y,
Zhang C, Chen J, Wang Y, Zhou R, et al: Pan-cancer analysis shapes
the understanding of cancer biology and medicine. Cancer Commun
(Lond). 45:728–746. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Knol JC, Lyu M, Böttger F, Nunes Monteiro
M, Pham TV, Rolfs F, Vallés-Martí A, Schelfhorst T, de Goeij-de
Haas RR, Bijnsdorp IV, et al: The pan-cancer proteome atlas, a mass
spectrometry-based landscape for discovering tumor biology,
biomarkers, and therapeutic targets. Cancer Cell. 43:1328–1346.e8.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bai L, Lyu J, Feng J, Qiao X, Qu Y, Yang
G, Zhu Y, Liao L, Gao H, Zang A, et al: Cancer biomarkers
discovered using pan-cancer plasma proteomic profiling. Nat Biomed
Eng. 10:16–38. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hao Q, Zhou T, Yan H, Ren Z, Mao W, Huang
LB, Chen YY, Wang Y, Xiao M, He Y, et al: A pan-cancer single cell
landscape reveals heterogeneity and functional diversity of
double-negative T cells. Mol Cancer. 25:242026. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lusby R, Demirdizen E, Inayatullah M,
Kundu P, Maiques O, Zhang Z, Terp MG, Sanz-Moreno V and Tiwari VK:
Pan-cancer drivers of metastasis. Mol Cancer. 24:22025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai F, Chen P, Chen L, Biskup E, Liu Y,
Chen PC, Chang JF, Jiang W, Jing Y, Chen Y, et al: Human RAD6
promotes G1-S transition and cell proliferation through
upregulation of cyclin D1 expression. PLoS One. 9:e1137272014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hong JH, Kaustov L, Coyaud E, Srikumar T,
Wan J, Arrowsmith C and Raught B: KCMF1 (potassium channel
modulatory factor 1) Links RAD6 to UBR4 (ubiquitin N-recognin
domain-containing E3 ligase 4) and lysosome-mediated degradation.
Mol Cell Proteomics. 14:674–685. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Somasagara RR, Spencer SM, Tripathi K,
Clark DW, Mani C, Madeira da Silva L, Scalici J, Kothayer H,
Westwell AD, Rocconi RP and Palle K: RAD6 promotes DNA repair and
stem cell signaling in ovarian cancer and is a promising
therapeutic target to prevent and treat acquired chemoresistance.
Oncogene. 36:6680–6690. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barnsby-Greer L, Mabbitt PD, Dery MA,
Squair DR, Wood NT, Lamoliatte F, Lange SM and Virdee S: UBE2A and
UBE2B are recruited by an atypical E3 ligase module in UBR4. Nat
Struct Mol Biol. 31:351–363. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ramatenki V, Potlapally SR, Dumpati RK,
Vadija R and Vuruputuri U: Homology modeling and virtual screening
of ubiquitin conjugation enzyme E2A for designing a novel selective
antagonist against cancer. J Recept Signal Transduct Res.
35:536–549. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Magistroni V, Mauri M, D'Aliberti D,
Mezzatesta C, Crespiatico I, Nava M, Fontana D, Sharma N, Parker W,
Schreiber A, et al: De novo UBE2A mutations are recurrently
acquired during chronic myeloid leukemia progression and interfere
with myeloid differentiation pathways. Haematologica.
104:1789–1797. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan Y, Nie Y, Peng C, Xing F, Ji S, Liu H
and Zhu C: The circular RNA hsa_circ_0001394 promotes
hepatocellular carcinoma progression by targeting the miR-527/UBE2A
axis. Cell Death Discov. 8:812022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wickham H: ggplot2: Elegant Graphics for
Data Analysis. Springer-Verlag; New York, NY: 2016, Available
from:. https://ggplot2.tidyverse.org
|
|
24
|
Chen D, Xu L, Xing H, Shen W, Song Z, Li
H, Zhu X, Li X, Wu L, Jiao H, et al: Sangerbox 2: Enhanced
functionalities and update for a comprehensive clinical
bioinformatics data analysis platform. Imeta. 3:e2382024.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Colak D, Nofal A, Albakheet A, Nirmal M,
Jeprel H, Eldali A, Al-Tweigeri T, Tulbah A, Ajarim D, Malik OA, et
al: Age-specific gene expression signatures for breast tumors and
cross-species conserved potential cancer progression markers in
young women. PLoS One. 8:e632042013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maire V, Némati F, Richardson M,
Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost
B, De Koning L, Lang G, et al: Polo-like kinase 1: A potential
therapeutic option in combination with conventional chemotherapy
for the management of patients with triple-negative breast cancer.
Cancer Res. 73:813–823. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ru B, Wong CN, Tong Y, Zhong JY, Zhong
SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, et al: TISIDB: An
integrated repository portal for tumor-immune system interactions.
Bioinformatics. 35:4200–4202. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Robin X, Turck N, Hainard A, Tiberti N,
Lisacek F, Sanchez JC and Müller M: pROC: An open-source package
for R and S+ to analyze and compare ROC curves. BMC Bioinformatics.
12:772011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lánczky A and Győrffy B: Web-based
survival analysis tool tailored for medical research (KMplot):
Development and implementation. J Med Internet Res. 23:e276332021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vasaikar SV, Straub P, Wang J and Zhang B:
LinkedOmics: Analyzing multi-omics data within and across 32 cancer
types. Nucleic Acids Res. 46:D956–D963. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Balakrishnan R, Harris MA, Huntley R, Van
Auken K and Cherry JM: A guide to best practices for Gene Ontology
(GO) manual annotation. Database (Oxford). 2013:bat0542013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Franz M, Rodriguez H, Lopes C, Zuberi K,
Montojo J, Bader GD and Morris Q: GeneMANIA update 2018. Nucleic
Acids Res. 46:W60–W64. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee AV, Nestler KA and Chiappinelli KB:
Therapeutic targeting of DNA methylation alterations in cancer.
Pharmacol Ther. 258:1086402024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu C, Xu X, Huang Y, Shang S and Ma L: RNA
methylation: A new promising biomaker in cancer liquid biopsy.
Biochim Biophys Acta Rev Cancer. 1880:1893372025. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chandrashekar DS, Karthikeyan SK, Korla
PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne
U, et al: UALCAN: An update to the integrated cancer data analysis
platform. Neoplasia. 25:18–27. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Racle J and Gfeller D: EPIC: A tool to
estimate the proportions of different cell types from bulk gene
expression data. Methods Mol Biol. 2120:233–248. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Plattner C, Finotello F and Rieder D:
Deconvoluting tumor-infiltrating immune cells from RNA-seq data
using quanTIseq. Methods Enzymol. 636:261–285. 2019.PubMed/NCBI
|
|
44
|
Aran D, Hu Z and Butte AJ: xCell:
Digitally portraying the tissue cellular heterogeneity landscape.
Genome Biol. 18:2202017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Han Y, Wang Y, Dong X, Sun D, Liu Z, Yue
J, Wang H, Li T and Wang C: TISCH2: Expanded datasets and new tools
for single-cell transcriptome analyses of the tumor
micro-environment. Nucleic Acids Res. 51:D1425–D1431. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Azizi E, Carr AJ, Plitas G, Cornish AE,
Konopacki C, Prabhakaran S, Nainys J, Wu K, Kiseliovas V, Setty M,
et al: Single-cell map of diverse immune phenotypes in the breast
tumor microenvironment. Cell. 174:1293–1308.e36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Savas P, Virassamy B, Ye C, Salim A,
Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S,
et al: Single-cell profiling of breast cancer T cells reveals a
tissue-resident memory subset associated with improved prognosis.
Nat Med. 24:986–993. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao R, Bai S, Henderson YC, Lin Y, Schalck
A, Yan Y, Kumar T, Hu M, Sei E, Davis A, et al: Delineating copy
number and clonal substructure in human tumors from single-cell
transcriptomes. Nat Biotechnol. 39:599–608. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wu SZ, Al-Eryani G, Roden DL, Junankar S,
Harvey K, Andersson A, Thennavan A, Wang C, Torpy JR, Bartonicek N,
et al: A single-cell and spatially resolved atlas of human breast
cancers. Nat Genet. 53:1334–1347. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zheng M: Super-high tumor mutational
burden predicts complete remission following immunotherapy: From
Peto's paradox to druggable cancer hallmark. J Immunother Cancer.
13:e0104862025. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Landre T and Des Guetz G: Microsatellite
instability-high status as a pan-cancer biomarker for immunotherapy
efficacy. Cancer Immunol Immunother. 74:1222025. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cheng X, Peng T, Chu T, Yang Y, Liu J, Gao
Q, Cao C and Wei J: Application of single-cell and spatial omics in
deciphering cellular hallmarks of cancer drug response and
resistance. J Hematol Oncol. 18:702025. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tirosh I and Suva ML: Cancer cell states:
Lessons from ten years of single-cell RNA-sequencing of human
tumors. Cancer Cell. 42:1497–1506. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI
|
|
56
|
Diao X, Guo C, Jin Y, Li B, Gao X, Du X,
Chen Z, Jo M, Zeng Y, Ding C, et al: Cancer situation in China: An
analysis based on the global epidemiological data released in 2024.
Cancer Commun (Lond). 45:178–197. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cordani M, Dando I, Ambrosini G and
González-Menéndez P: Signaling, cancer cell plasticity, and
intratumor heterogeneity. Cell Commun Signal. 22:2552024.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Shen JD, Fu SZ, Ju LL, Wang YF, Dai F, Liu
ZX, Ji HZ, Shao JG and Bian ZL: High expression of
ubiquitin-conjugating enzyme E2A predicts poor prognosis in
hepatocellular carcinoma. Oncol Lett. 15:7362–7368. 2018.PubMed/NCBI
|
|
59
|
Zou R, Xu H, Li F, Wang S and Zhu L:
Increased expression of UBE2T predicting poor survival of
epithelial ovarian cancer: Based on comprehensive analysis of
UBE2s, clinical samples, and the GEO database. DNA Cell Biol.
40:36–60. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rosner K, Mehregan DR, Kirou E, Abrams J,
Kim S, Campbell M, Frieder J, Lawrence K, Haynes B and Shekhar MP:
Melanoma development and progression are associated with Rad6
Upregulation and β-catenin relocation to the cell membrane. J Skin
Cancer. 2014:4392052014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zamani-Ahmadmahmudi M, Nassiri SM and
Soltaninezhad F: Development of an RNA sequencing-based prognostic
gene signature in multiple myeloma. Br J Haematol. 192:310–321.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Berdasco M and Esteller M: Clinical
epigenetics: Seizing opportunities for translation. Nat Rev Genet.
20:109–127. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang Z, Strasser A and Kelly GL: Should
mutant TP53 be targeted for cancer therapy? Cell Death Differ.
29:911–120. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hauseman ZJ, Stauffer F, Beyer KS, Mollé
S, Cavicchioli E, Marchand JR, Fodor M, Viscomi J, Dhembi A, Katz
S, et al: Targeting the SHOC2-RAS interaction in RAS-mutant
cancers. Nature. 642:232–241. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
de Miranda NFCC, Georgiou K, Chen L, Wu C,
Gao Z, Zaravinos A, Lisboa S, Enblad G, Teixeira MR, Zeng Y, et al:
Exome sequencing reveals novel mutation targets in diffuse large
B-cell lymphomas derived from Chinese patients. Blood.
124:2544–2553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
de Visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zeng D, Yu Y, Qiu W, Ou Q, Mao Q, Jiang L,
Wu J, Wu J, Luo H, Luo P, et al: Immunotyping the tumor
microenvironment reveals molecular heterogeneity for personalized
immunotherapy in cancer. Adv Sci (Weinh). 12:e24175932025.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Cheng M, Chen S, Li K, Wang G, Xiong G,
Ling R, Zhang C, Zhang Z, Han H, Chen Z, et al: CD276-dependent
efferocytosis by tumor-associated macrophages promotes immune
evasion in bladder cancer. Nat Commun. 15:28182024. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Baessler A and Vignali DAA: T cell
exhaustion. Annu Rev Immunol. 42:179–206. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chen S, Wang DL, Liu Y, Zhao L and Sun FL:
RAD6 regulates the dosage of p53 by a combination of
transcriptional and posttranscriptional mechanisms. Mol Cell Biol.
32:576–587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chen S, Wang C, Sun L, Wang DL, Chen L,
Huang Z, Yang Q, Gao J, Yang XB, Chang JF, et al: RAD6 promotes
homologous recombination repair by activating the
autophagy-mediated degradation of heterochromatin protein HP1. Mol
Cell Biol. 35:406–416. 2014. View Article : Google Scholar : PubMed/NCBI
|
